Case number 1:23-cv-00150
Actelion Pharmaceuticals US, Inc. et al v. Lupin Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 20, 2024 | 12 | Report to the Commissioner of Patents and Trademarks. (ntl) (Entered: 02/20/2024) (4) |
| Feb 14, 2024 | 11 | CONSENT JUDGMENT and Order of Permanent Injunction. Signed by Judge Gregory B. Williams on 2/14/24. (ntl) (Entered: 02/14/2024) (3) |
| Feb 12, 2024 | 10 | PROPOSED CONSENT JUDGMENT and Permanent Injunction as to Lupin Defendants only by Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc., Nippon Shinyaku Co., Ltd., Actelion Pharmaceuticals Ltd.. (Mayo, Andrew) (Entered: 02/12/2024) (3) |
| Apr 4, 2023 | 9 | STIPULATION Regarding Consolidation of Actions and Extension of Deadline for Submission of Proposed Scheduling Order, by Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc., Nippon Shinyaku Co., Ltd., Actelion Pharmaceuticals Ltd.. (Balick, Steven) (Entered: 04/04/2023) (3) |
| Mar 10, 2023 | 7 | WAIVER OF SERVICE returned executed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd., Nippon Shinyaku Co., Ltd.: For Lupin Ltd. waiver sent on 3/7/2023, answer due 5/8/2023. (Balick, Steven) (Entered: 03/10/2023) (1) |
| Mar 10, 2023 | 8 | WAIVER OF SERVICE returned executed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd., Nippon Shinyaku Co., Ltd.: For Lupin Pharmaceuticals, Inc. waiver sent on 3/7/2023, answer due 5/8/2023. (Balick, Steven) (Entered: 03/10/2023) (1) |
| Feb 9, 2023 | 1 | Complaint* (1) |
| Feb 9, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 02/09/2023) (3) |
| Feb 9, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/5/2023. Date of Expiration of Patent: 6/25/2030 for U.S. Patent No. 9,284,280, and 8/1/2030 for U.S. Patent No. 8,791,122. Thirty Month Stay Deadline: 7/5/2025. (mkr) (Entered: 02/09/2023) (2) |
| Feb 9, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,791,122; and 9,284,280. (mkr) (Entered: 02/09/2023) (1) |
| Feb 9, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Actelion Pharmaceuticals Ltd. and Actelion Pharmaceuticals US, Inc. filed by Actelion Pharmaceuticals Ltd. and Actelion Pharmaceuticals US, Inc. (mkr) (Entered: 02/10/2023) (2) |
| Feb 9, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nippon Shinyaku Co., Ltd. (mkr) (Entered: 02/10/2023) (1) |
